CD274 and neoplasm: Recently, cancer immunotherapy, including blockade of inhibitory immune checkpoints (such as PD-1/PD-L1 and CTLA-4), has emerged as an unprecedented breakthrough for the treatment of cancer that can induce long-term tumor regression (10, –12).